Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction

• Published in: Neurobiology of aging Vol. 106; pp. 12 - 25
• Main Authors: Gentzel, Renee C, Toolan, Dawn, Jinn, Sarah, Schachter, Joel B, Ma, Lei, Kahle, Philipp J, Smith, Sean M, Marcus, Jacob N
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2021
• Subjects: A30P; Alpha-Synuclein; alpha-Synuclein - administration & dosage; alpha-Synuclein - adverse effects; alpha-Synuclein - genetics; alpha-Synuclein - metabolism; Animals; Disease Models, Animal; Gene Expression; Mice, Transgenic; Microglia - pathology; Parkinson Disease - etiology; Parkinson Disease - genetics; Parkinson Disease - pathology; Parkinson's Disease; Synucleinopathies - etiology; Synucleinopathies - genetics; Synucleinopathies - pathology; Transgenic mice; pS129; Transgenic mice; HOM; SNc; Alpha-Synuclein; Parkinson's Disease; Iba1; A30P; LPS; PFF; TH; AAV; HET; PAG; αSyn; MPTP; PK; SN; WT
• ISSN: 0197-4580; 1558-1497
• DOI: 10.1016/j.neurobiolaging.2021.05.012

Synucleinopathies are neurodegenerative disorders involving pathological alpha-synuclein (αSyn) protein, including dementia with Lewy bodies, multiple system atrophy and Parkinson's disease (PD). Current in vivo models of synucleinopathy include transgenic mice overexpressing αSyn variants and methods based on administration of aggregated, exogenous αSyn. Combining these techniques offers the ability to study consequences of introducing pathological αSyn into primed neuronal environments likely to develop synucleinopathy. Herein, we characterize the impacts pre-formed fibrils (PFFs) of recombinant, human αSyn have in mice overexpressing human A30P αSyn, a mutation associated with autosomal dominant PD. A30P mouse brain contains detergent insoluble αSyn biochemically similar to PD brain, and these mice develop Lewy-like synucleinopathy with age. Administration of PFFs in A30P mice resulted in regionally-specific accumulations of phosphorylated synuclein, microglial induction and a motor phenotype that differed from PFF-induced effects in wildtype mice. Surprisingly, PFF-induced losses of tyrosine hydroxylase were similar in A30P and wildtype mice. Thus, the PFF-A30P model recapitulates key aspects of synucleinopathy with induction of microglia, creating an appropriate system for evaluating neurodegenerative therapeutics.